Khalaf, M., Karmoosh, A., Hamo, A., Mohammed, Z. (2023). The Relationship Between Eye Diseases and Toxic Thyroid Gland: A Concentrated Study. Alustath, 20(1), 60-64. doi: 10.33899/iphr.2023.139757.1039
Muthanna Taha Khalaf; Ahmed Shuaib Karmoosh; Akram Ahmed Hamo; Zinah Jasim Mohammed. "The Relationship Between Eye Diseases and Toxic Thyroid Gland: A Concentrated Study". Alustath, 20, 1, 2023, 60-64. doi: 10.33899/iphr.2023.139757.1039
Khalaf, M., Karmoosh, A., Hamo, A., Mohammed, Z. (2023). 'The Relationship Between Eye Diseases and Toxic Thyroid Gland: A Concentrated Study', Alustath, 20(1), pp. 60-64. doi: 10.33899/iphr.2023.139757.1039
Khalaf, M., Karmoosh, A., Hamo, A., Mohammed, Z. The Relationship Between Eye Diseases and Toxic Thyroid Gland: A Concentrated Study. Alustath, 2023; 20(1): 60-64. doi: 10.33899/iphr.2023.139757.1039

The Relationship Between Eye Diseases and Toxic Thyroid Gland: A Concentrated Study

Iraqi Journal of Pharmacy
Article 9, Volume 20, Issue 1, June 2023, Pages 60-64    PDF (469.2 K)
Document Type: Review Paper
DOI: 10.33899/iphr.2023.139757.1039
Authors
Muthanna Taha Khalaf* 1; Ahmed Shuaib Karmoosh2; Akram Ahmed Hamo3; Zinah Jasim Mohammed4
1Medical research centers, Nineveh Health Directorate, Ministry of Health, Iraq
2Nineveh Health Directorate, Ministry of Health, Iraq
3The primary health care sector in Al-Baaj, Nineveh Health Directorate, Ministry of Health, Iraq
4Left Section, Nineveh Health Directorate, Ministry of Health, Iraq
Abstract
Background: When the thyroid gland becomes overactive or underactive, a variety of health issues may occur, including eye illnesses. Thyroxine (T4) and triiodothyronine (T3) are the two primary hormones produced by the thyroid gland. These hormones are essential for maintaining of proper eye function. When the thyroid gland is hyperactive, it can cause a variety of eye disorders for example Graves' ophthalmopathy. Aim: To explore the potential link between eye disorders and toxic thyroid glands, specifically how hyperthyroidism (an overactive thyroid gland) may contribute to the development of eye conditions like Graves' ophthalmopathy. . The ultimate goal is to enhance patient outcomes through better knowledge and management of these complicated illnesses. Patients and Methods: The second survey questionnaire was completed by 100 patients with thyroid disorders. Several approaches are available to assess the link between ocular problems and toxic thyroid glands. Among these methods are Thyroid Function Tests and a Comprehensive Eye Exam: Thyroid function tests include measuring the plasma levels of TSH, T3, and T4 levels to see if there is an underlying thyroid gland dysfunction which may produce abnormalities in the eyes. Results: The study included 100 patients, with 81% of them being women.  Individual ocular problems are more common in male than in female patients. Exophthalmos was reported by about 70% of the men (the most frequently). Patients also frequently reported redness of the eyes (68%), edema or swelling of the eyelids (67%), and ocular dryness (61%). They were less likely to have a hazy vision, but about one-third did. Conclusion: Hyperthyroidism and Graves' disease can lead to eye problems such as bulging eyes, double vision, dry eyes, and sensitivity to light. It is important to have regular eye exams and seek medical attention if any changes occur.  
Keywords
Eye diseases; Toxic thyroid gland; Graves' disease
References
  1. Gerberi D. Thyroid Disorders: A Webliography. Journal of Consumer Health on the Internet. 2019;23(4):419–28.
  2. Temiz Karadag D, Cetinarslan B, Kasap M, Canturk NZ, Akpinar G, Canturk Z, et al. Proteomic analysis of thyroid tissue reveals enhanced catabolic activity in Graves’ disease compared to toxic multinodular goitre. Cell Biochemistry and Function. 2021;39(5):658–66.
  3. Balwan WK, Kour S. Thyroid Health & Methylation: What is the Link. Scholars Journal of Applied Medical Sciences. 2022;12:2460–8.
  4. Evereklioglu C. Current concepts in the etiology and treatment of Behçet disease. Survey of ophthalmology. 2005;50(4):297–350.
  5. Gupta A, Sadeghi PB, Akpek EK. Occult thyroid eye disease in patients presenting with dry eye symptoms. American journal of ophthalmology. 2009;147(5):919–23.
  6. Danchaivijitr C, Kennard C. Diplopia and eye movement disorders. Journal of Neurology, Neurosurgery & Psychiatry. 2004;75(suppl 4):iv24–31.
  7. Grove Jr AS. Eyelid retraction treated by levator marginal myotomy. Ophthalmology. 1980;87(10):1013–8.
  8. Hutchings KR, Fritzhand SJ, Esmaeli B, Koka K, Zhao J, Ahmed S, et al. Graves’ Eye Disease: Clinical and Radiological Diagnosis. Biomedicines. 2023;11(2):312.
  9. Menconi F, Marcocci C, Marinò M. Diagnosis and classification of Graves’ disease. Autoimmunity reviews. 2014;13(4–5):398–402.
  10. Plazinska MT, Sawicka-Gutaj N, Czarnywojtek A, Wolinski K, Kobylecka M, Karlińska M, et al. Radioiodine therapy and Graves’ disease–Myths and reality. Plos one. 2020;15(1):e0226495.
  11. Biscarini F, Masetti G, Muller I, Verhasselt HL, Covelli D, Colucci G, et al. Gut microbiome associated with Graves disease and Graves orbitopathy: the INDIGO Multicenter European Study. The Journal of Clinical Endocrinology & Metabolism. 2023;dgad030.
  12. Jawad NK, Numan AT, Ahmed AG, Saleh TH, Al-Rubaii BAL. IL-38 gene expression: A new player in Graves’ ophthalmopathy patients in Iraq. Biomedicine. 2023;43(1):210–5.
  13. Caroline YY, Keen JA, Shriver EM. Teprotumumab: A Major Advance in the Treatment of Thyroid Eye Disease Management. Advances in Ophthalmology and Optometry. 2022;7(1):383–400.
  14. Alanazi SA, Alomran AA, Abusharha A, Fagehi R, Al-Johani NJ, El-Hiti GA, et al. An assessment of the ocular tear film in patients with thyroid disorders. Clinical Ophthalmology. 2019;1019–26.
  15. Woodfield D, Tanner DL. Complicated Neurotrophic Corneal Ulcer in a Patient with Multiple Autoimmune Disorders. CRO (Clinical & Refractive Optometry) Journal. 2022;33(4).
  16. Du B, Wang Y, Yang M, He W. Clinical features and clinical course of thyroid-associated ophthalmopathy: a case series of 3620 Chinese cases. Eye. 2021;35(8):2294–301.
  17. Mohamed HB, Abd El-Hamid BN, Fathalla D, Fouad EA. Current trends in pharmaceutical treatment of dry eye disease: A review. European Journal of Pharmaceutical Sciences. 2022;106206.
  18. Shah R, Amador C, Tormanen K, Ghiam S, Saghizadeh M, Arumugaswami V, et al. Systemic diseases and the cornea. Experimental eye research. 2021;204:108455.
  19. Ismael RN, Mustafa YF, Al-Qazaz HK. Coumarin-based products: Their biodiversity and pharmacology. Iraqi Journal of Pharmacy. 2022;18(2):162–79.
  20. Castro BDL, Sobral SEF, de Santana Pereira PH, Cordeiro AL, Santos SD, Costa AAS, et al. Ophthalmological profile of patients with thyroid diseases in Fortaleza, Ceará, Brazil: glaucoma investigation. Journal of Health & Biological Sciences. 2021;9(1):1–5.
  21. Liaboe CA, Simmons BA, Clark TJ, Shriver EM. Thyroid Eye Disesase, patient information (2023).
  22. Shohieb AM, Shawky N, Shoma A. Immunotherapy forthyroid eye disesase. Mansoura Medical Journal. 2022;51(1):9–22.
  23. Hsia Y, Hsiao CC, Wei YH, Lai IW, Lin CW, Liao SL. The changes in optic nerve after orbital decompression surgery for thyroid eye disease and case reports of ischemic optic neuropathy. BioMed Research International. 2022;2022.
  24. Lanzolla G, Puccinelli L, Giudetti M, Comi S, Menconi F, Maglionico MN, et al. Anti-nuclear autoantibodies in Graves’ disease and Graves’ orbitopathy. Journal of Endocrinological Investigation. 2023;46(2):337–44.
  25. Hansen M, Johnson A, Weber KS, O’Neill KL. Characterizing the Interplay of Lymphocytes in Graves’ Disease. International Journal of Molecular Sciences. 2023;24(7):6835.
Statistics
Article View: 226
PDF Download: 143


Journal Management System. Powered by ejournalplus.com